
-
Xenon Pharmaceuticals NasdaqGM:XENE Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Location: 200-3650 Gilmore Way, Burnaby, BC, V5G 4W8, Canada | Website: https://www.xenon-pharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.687B
Cash
549.6M
Avg Qtr Burn
-49.21M
Short % of Float
4.90%
Insider Ownership
0.26%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XEN1101 Details Epilepsy, Seizures, Primary Generalized Tonic Clonic Seizures | Phase 3 Data readout | |
XEN1101 (Potassium Channel Modulator) Details Epilepsy, Focal Onset Seizures | Phase 3 Data readout | |
XEN1101 Details Mental health, Major depressive disorder | Phase 3 Initiation | |
Azetukalner (XEN1101) Details Epilepsy, Focal Onset Seizures | Phase 2b Update | |
XEN901/NBI-921352 Details Epilepsy, Focal Onset Seizures | Phase 2 Update | |
Phase 1 Initiation | ||
XEN1701 (Nav1.7 candidate) Details No defined indication | IND Submission | |
XEN007 (Calcium Channel Inhibitor) Details Epilepsy, Multiple sclerosis | Failed Discontinued | |
Failed Discontinued |